633. Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)

BACKGROUND: ADG20 is a fully human IgG1 monoclonal antibody engineered to have high potency and broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other SARS-like CoVs with pandemic potential by binding to a highly conserved epitope in the receptor-binding...

Descripción completa

Detalles Bibliográficos
Autores principales: Paguntalan, Helen, Magyarics, Zoltán, Connolly, Lynn E, Hershberger, Ellie, Narayan, Kristin, Gupta, Deepali, Ambrose, Paul G, Engler, Frank, Campanaro, Ed, Das, Anita F, Schmidt, Pete
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690762/
http://dx.doi.org/10.1093/ofid/ofab466.831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690762/
http://dx.doi.org/10.1093/ofid/ofab466.831

Ejemplares similares